Ann Dermatol.  2017 Feb;29(1):111-113. 10.5021/ad.2017.29.1.111.

Immune Parameters of Korean Patients with Psoriasis Treated with Low-Dose Cyclosporine

• Choi JH
• Shin EJ
• Shin MK
• Kim NI

• KMID: 2368042
• DOI: http://doi.org/10.5021/ad.2017.29.1.111

Abstract

No abstract available.

MeSH Terms

Cyclosporine*
Humans
Psoriasis*
Cyclosporine

Figure

• 

  Fig. 1 (A) Average differences in cell counts between the two groups, by cell type. (B) Differences in average cell counts during the cyclosporine dosing period. NK: natural killer.

Reference

1. Wicker LS, Boltz RC Jr, Matt V, Nichols EA, Peterson LB, Sigal NH. Suppression of B cell activation by cyclosporin A, FK506 and rapamycin. Eur J Immunol. 1990; 20:2277–2283.

2. Morteau O, Blundell S, Chakera A, Bennett S, Christou CM, Mason PD, et al. Renal transplant immunosuppression impairs natural killer cell function in vitro and in vivo. PLoS One. 2010; 5:e13294.

3. Amor KT, Ryan C, Menter A. The use of cyclosporine in dermatology: part I. J Am Acad Dermatol. 2010; 63:925–946. quiz 947-948.

4. Cerman AA, Bozkurt S, Sav A, Tulunay A, Elbaşi MO, Ergun T. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol. 2008; 159:820–826.

5. Swimberghe S, Ghislain PD, Daci E, Allewaert K, Denhaerynck K, Hermans C, et al. Clinical, quality of life, patient adherence, and safety outcomes of short-course (12 weeks) treatment with cyclosporine in patients with severe psoriasis (the practice study). Ann Dermatol. 2013; 25:28–35.

6. Giese T, Zeier M, Schemmer P, Uhl W, Schoels M, Dengler T, et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation. 2004; 77:339–344.

7. Brandt C, Pavlovic V, Radbruch A, Worm M, Baumgrass R. Low-dose cyclosporine A therapy increases the regulatory T cell population in patients with atopic dermatitis. Allergy. 2009; 64:1588–1596.

8. Miroux C, Moralès O, Carpentier A, Dharancy S, Conti F, Boleslowski E, et al. Inhibitory effects of cyclosporine on human regulatory T cells in vitro. Transplant Proc. 2009; 41:3371–3374.

9. Takashima A, Morita A. Genomic, phenotypic, and functional analyses of T cells in patients with psoriasis undergoing systemic cyclosporin A treatment. J Invest Dermatol. 1991; 96:376–382.

10. Wang H, Grzywacz B, Sukovich D, McCullar V, Cao Q, Lee AB, et al. The unexpected effect of cyclosporin A on CD56+ CD16- and CD56+CD16+ natural killer cell subpopulations. Blood. 2007; 110:1530–1539.